Calendar
Filter Events
July 2024
Clinical Overview of Investigational Menin Inhibitor for the Treatment of KMT2A-Rearranged R/R Acute Leukemia
A Pre-Approval Information Exchange (PIE) Webinar, sponsored by Syndax Pharmaceuticals.
Pre-Approval Information Exchange (PIE) presentation for investigational revumenib, including a clinical overview, burden of disease, and disease background for pediatric and adult patients harboring KMT2A-rearranged relapsed or refractory acute leukemia.
This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.
This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.
MEMBERS
NON-MEMBERS
July 2024
Managed Care Consensus Recommendations to Facilitate Equitable Access and Optimal Outcomes for Retinal Diseases
A Science & Innovation Webinar, sponsored by Impact Education, LLC.
Retinal diseases result in remarkable morbidity among plan members, including vision loss and blindness. Furthermore, disparities exist in incidence and outcomes among those affected by social determinants of health (SDOH). This webcast, presented by ManagedCareEye.com, will educate managed care and payer professionals regarding best practices in enhancing retinal disease care equity and access.
Learning Objectives
- Identify current disparities in the care of retinal diseases.
- Outline the importance of anti-VEGF therapies with extended duration of effect for patients impacted by SDOH.
- Describe means by which to address the impact of SDOH via utilization management programs.
MEMBERS
NON-MEMBERS
July 2024
An IL-23 for the Treatment of Moderate to Severe Ulcerative Colitis
A Science & Innovation Webinar, sponsored by Abbvie.
Ulcerative colitis is a chronic, progressive, inflammatory bowel disease that damages the bowel over time and may result in decreased quality of life, hospitalizations, surgeries, and disability. The STRIDE II Recommendations for moderate to severe ulcerative colitis include long-term goals for the management of the disease.
There is a need for new treatment options, with a focus on long-term patient outcomes. An IL-23 inhibitor was recently approved for the treatment of moderate to severe ulcerative colitis. The objective of this webinar is to review the ulcerative colitis disease state, treatment guidelines, and the pivotal trials program for this recently approved indication for an IL-23 inhibitor.
MEMBERS
NON-MEMBERS
July 2024
AMCP Market Insights: Enhancing Patient Outcomes and Cost Management in Wet AMD
Neovascular, or wet, age-related macular degeneration (wet AMD) is a significant cause of central visual impairment, contributing to about half of all cases of blindness in Americans aged 50 years and older. The estimated number of individuals affected by wet AMD in the United States is projected to double to 5.4 million between 2010 and 2050. Although there is currently no cure for wet AMD, there are treatment options that slow disease progression.
In this webinar, key panelists will share insights curated from AMCP's Market Insights program on the patient burden of wet AMD and how payers can best manage it by considering factors such as timeliness of treatment, treatment durability, and cost-effective treatment strategies.
MEMBERS
NON-MEMBERS
July 2024
Select 2023 EULAR & 2024 KDIGO Lupus Recommendations: Considerations for Your Patient Population
A Science & Innovation Webinar, sponsored by GSK.
Lupus is a disease of progressive, and often irreversible, organ damage. It is more common in women and non-white populations. Factors such as long-term use of corticosteroids, high disease activity and flares may increase the risk of organ damage, while lupus nephritis may lead to significant chronic kidney disease, and potentially end stage kidney disease. Recently updated EULAR and KDIGO guidelines reflect up-to-date evidence and expert consensus and may be applied to your populations to improve patient outcomes, including minimizing toxicities, flares and risk of organ damage progression.
MEMBERS
NON-MEMBERS
August 2024
September 2024
Midwest AMCP 2024 Michigan Day of Education
Join Midwest AMCP and your peers for education and networking at this popular Midwest AMCP Day of Education on Friday, September 20 in Detroit, Michigan.
October 2024
Northeast AMCP 2024 Day of Education
Join Northeast AMCP and your peers at the 2nd Annual Day of Education in New York. You will hear perspectives and gain valuable insights from a variety of healthcare professionals representing various roles (e.g., Pharmacists, managed care leaders from PBMs, Health plans, and AMCP leaders). CE credits will be available.
October 2024
AMCP Nexus 2024
- Call for Session Proposals - submission portal opens Mar. 18, 2024
- Call for Poster Abstracts - submission portal opens Mar. 18, 2024
- Registration opens Jul. 9, 2024 for members, Jul. 11, 2024 for all
November 2024
Midwest AMCP 2024 Chicago Day of Education
Join Midwest AMCP and your peers for education and networking at this popular Midwest AMCP Day of Education on Friday, November 22, in Chicago, IL.
March 2025
AMCP 2025
- Registration opens for AMCP 2025 in Houston on December 3, 2024.
- Call for Session Proposals Submission Portal Open August 19-September 23, 2024.
- Call for Poster Abstracts Submission Portal Open August 19-October 31, 2024.